BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26891375)

  • 1. Alleviating anemia and thrombocytopenia in myelofibrosis patients.
    Cervantes F; Correa JG; Hernandez-Boluda JC
    Expert Rev Hematol; 2016 May; 9(5):489-96. PubMed ID: 26891375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing patients with myelofibrosis and thrombocytopenia.
    Yilmaz M; Verstovsek S
    Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
    Sastow D; Mascarenhas J; Tremblay D
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide.
    Tremblay D; Baine I; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1067-e1074. PubMed ID: 36117043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing patients with myelofibrosis and low platelet counts.
    Al-Ali HK; Vannucchi AM
    Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for the treatment of myelofibrosis.
    Mesa RA
    Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.
    Boruchov AM
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S37-43. PubMed ID: 19245933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal (marker) chromosomes in two patients with acute myelofibrosis.
    Mitus WJ; Coleman N; Kiossoglou KA
    Arch Intern Med; 1969 Feb; 123(2):192-7. PubMed ID: 5763618
    [No Abstract]   [Full Text] [Related]  

  • 10. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
    Saeed I; McLornan D; Harrison CN
    Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
    Mesa RA; Quintás-Cardama A; Verstovsek S
    Curr Hematol Malig Rep; 2007 Feb; 2(1):25-33. PubMed ID: 20425385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
    Shanavas M; Gupta V
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and old treatment modalities in primary myelofibrosis.
    Cervantes F; Mesa R; Barosi G
    Cancer J; 2007; 13(6):377-83. PubMed ID: 18032975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
    Cervantes F; Isola IM; Alvarez-Larrán A; Hernández-Boluda JC; Correa JG; Pereira A
    Ann Hematol; 2015 Nov; 94(11):1791-6. PubMed ID: 26122869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern management of myelofibrosis.
    Cervantes F
    Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
    Alchalby H; Kröger N
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Barosi G; Bacigalupo A
    Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
    Tefferi A; Mesa RA; Nagorney DM; Schroeder G; Silverstein MN
    Blood; 2000 Apr; 95(7):2226-33. PubMed ID: 10733489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.